Differential Treatment Effectiveness in Patients with the melancholic sub-type of depressio

Not Applicable

Recruiting

• Conditions: Melancholic Depression; Mental Health - Depression

• Registration Number: ACTRN12609000052235
• Lead Sponsor: niversity of New South Wales

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-01-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

1. Age between 18 and 65 years. 2. Current episode of depression, duration between 4 weeks and 2 years. 3. Diagnostic Statistical Manual IV (DSM-IV) diagnosis of Major Depressive Disorder (with melancholic features) and having a QIDS-SR score of 11 or more (= a score of 14 or more on the Hamilton Depression Scale).

Exclusion Criteria

1. More than one failed antidepressant treatment trial. 2. Currently pregnant or breast feeding. 3. Taken antidepressant medication within twelve months. 4. Currently seeing a psychologist. 5. Undergone cognitive behavioural therapy in the last five years. 6. Suicide risk. 7. Comorbid diagnoses of obsessive compulsive disorder, psychosis, bipolar disorder or eating disorder. 8. Current substance abuse or dependence.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To measure severity of participants' symptoms of melancholic depression.[The Hamilton Rating Scale for Depression (HRSD) and The CORE Assessment of Psychomotor Change will be administered by a blind assessor at baseline, and weeks 4, 8 and 12. The total HRSD score will be the primary outcome along with the endogenous subscale of the HRSD.]

Secondary Outcome Measures

Name	Time	Method
Effect of depression on participants life[16 item Quality of Life Enjoyment and Satisfaction Questionnaire (QOL), Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR), 5 item Work Productivity and Activity Impairment (WPAI) will be completed at baseline, weeks 2, 4, 6, 8, 10 and 12. 16 item Quality of Life Enjoyment and Satisfaction Questionnaire (QOL) and 5 item Work Productivity and Activity Impairment (WPAI) both measure the extent to which the participant's depression affects their everyday life, and work performance, respectively. Each participant will also complete daily mood charting via the Daily Rating Scale (DRS) questionnaire.]